News
Auron Strengthens Board of Directors and Leadership Team with Industry Veterans, Victoria Richon, Ph.D. and Christopher Guiffre, J.D., MBA
Dr. Vicky Richon, Appointed to Board of Directors; Chris Guiffre Appointed President and Chief Operating Officer Newton, MA, Aug 10, 2023 – Auron Therapeutics, a platform-based, product-driven biotechnology company focused on discovering and developing novel cancer therapies using its AI-powered platform, today announced appointments to its board of directors and management team. Victoria Richon, Ph.D.,…
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer
Advisory Board includes recognized physicians, clinicians and scientists with deep expertise spanning multi-omic platforms, translational biology, drug discovery and clinical development Newton, MA, August 1, 2023 – Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular plasticity, today announced the members of its scientific advisory board (SAB), comprised…
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
Wellesley, Mass., Jan. 27, 2021 – Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing differentiation therapies for treating cancer, today announced the completion of its $12.75 million seed financing round. Proceeds will be used to discover and develop novel therapeutics directed toward differentiation therapy, which reactivates endogenous cellular programs to elicit tumor cell maturation…